Diamantas was elevated after Commissioner Marty Makary resigned.
Food and Drug Administration (FDA) Acting Commissioner Kyle Diamantas called pro-life organizations to offer reassurance about his commitment to life after some people in the movement raised concerns.
“Acting Commissioner Kyle Diamantas is personally committed to delivering on President Trump’s pro-life and pro-family agenda at the FDA,” Andrew Nixon, deputy assistant secretary for media relations at the U.S. Department of Health and Human Services, told EWTN News.
“Both he and other administration officials will continue regularly interacting with stakeholders in this community to inform FDA decision-making,” he said.
Diamantas is serving as acting commissioner after the May 12 resignation of Commissioner Marty Makary, who faced criticism from within the pro-life movement for failure to impose stricter regulations on the abortion drug mifepristone.
Some pro-life leaders celebrated Makary’s departure but grew concerned about Diamantas because court records show him serving as legal counsel for a Planned Parenthood affiliate while working at the Baker Donelson law firm. The case was related to a property dispute.
Alex Bruesewitz, an adviser to President Donald Trump, dismissed the concern in a post on X, saying he was a junior associate assigned to the case but removed
